Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report

Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce. In this study, we reported the humoral immunogenicity of an mRNA booster 90–180 days after completin...

Descripción completa

Detalles Bibliográficos
Autores principales: Intapiboon, Porntip, Pinpathomrat, Nawamin, Juthong, Siriporn, Uea-Areewongsa, Parichat, Ongarj, Jomkwan, Siripaitoon, Boonjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054473/
https://www.ncbi.nlm.nih.gov/pubmed/36992120
http://dx.doi.org/10.3390/vaccines11030537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054473/
https://www.ncbi.nlm.nih.gov/pubmed/36992120
http://dx.doi.org/10.3390/vaccines11030537

Ejemplares similares